Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Identification of channelrhodopsin-2 (CHR2) mutations and methods of use

a technology of channelrhodopsin and chr2 is applied in the field of molecular biology, which can solve the problems of reduced visual acuity, reduced photoreceptor loss or degeneration, and reduced photoreceptor function, so as to improve photocurrent, reduce threshold light intensity, and high temporal resolution

Pending Publication Date: 2022-02-03
WAYNE STATE UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a mutant protein called Chop2 that can be used to restore or improve vision. Mutations at certain amino acid positions in Chop2 make it easier to detect light and generate an electrical signal. The double mutant version of Chop2 has even greater sensitivity to light than the single mutant. These mutant proteins can be used alone or in combination to restore or improve vision. This technology has the potential to help millions of people who have lost their vision due to retinal degeneration.

Problems solved by technology

Photoreceptor loss or degeneration severely compromises, if not completely inhibits, phototransduction of visual information within the retina.
Loss of photoreceptor cells and / or loss of a photoreceptor cell function are the primary causes of diminished visual acuity, diminished light sensitivity, and blindness.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Identification of channelrhodopsin-2 (CHR2) mutations and methods of use
  • Identification of channelrhodopsin-2 (CHR2) mutations and methods of use
  • Identification of channelrhodopsin-2 (CHR2) mutations and methods of use

Examples

Experimental program
Comparison scheme
Effect test

example 1

n of Labeled Mutant Chop2 Constructs

[0113]Mutations were made on a codon optimized Chop2-GFP fusion protein to create single and double mutations at the L132 (Leucine 132) and T159 (Threonine 159) sites. Several mutants were generated, for example, single mutants such as L132A, L132C, T159A, T159C, and T 159S, and double mutants such as L132C / T159C, L132C / T159S, L132A / T159C, and L132C / T159A. Chop2-GFP transgenes were cloned into a rAAV vector under the control of a CAG promoter using methods known in the art.

example 2

Analysis of Mutant Chop2 Constructs

[0114]The functional properties of each mutant Chop2, or a combination thereof, were first examined in HEK cells. Chop2 constructs were delivered to HEK cells by adenoviral infection, for example. Upon expression of the WT or mutant Chop2, functional WT and mutant ChR2 channels were formed. Measurements of the light sensitivity and other properties of the ChR2 channels were assessed as described herein. The light stimuli (photons / cm2·s at 460 nm) were generated by a xenon arc lamp and attenuated by neutral density filters: ND4.0 (2.8×1014), ND3.0 (1.4×1015), ND2.5 (4.8×1015); ND2.0 (1.6×1016), ND1.0 (1.3×1017), ND0 (1.2×1018). Light evoked currents were measured from wild-type ChR2, T159C, L132C, L132C / T159C, and L132C / T159S. Patch clamp recordings were performed using methods known in the art.

[0115]Representative recordings from this experiment comparing light sensitivity between the Chop2 constructs demonstrated that mutations at L132 alone or in...

example 3

cular Administration and Analysis of Mutant Chop2 Constructs

[0117]AAV2 virus vectors carrying mutant Chop2-GFP constructs driven by CAG promoter were made and injected intravitreally into the eyes of C57BL / 6J adult mice. Adult mice were anesthetized by IP injection of ketamine (100 mg / kg) and xylazine (10 mg / kg). Under a dissecting microscope, an incision was made by scissors through the eyelid to expose the sclera. A small perforation was made in the sclera region posterior to the lens with a needle and viral vector suspension of 0.8-1.5 μl at the concentration of approximately 1011 genomic particles / ml was injected into intravitreal space through the hole with a Hamilton syringe with a 32-gauge blunt-ended needle. For each animal, usually only one eye was injected with viral vectors carrying a Chop2 construct, and the other eye was uninjected or injected with control viral vectors carrying GFP alone. Upon expression of the WT or mutant Chop2 of the present invention, functional WT...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides compositions and kits including at least one nucleic acid or polypeptide molecule encoding for a mutant ChR2 protein. Methods of the invention include administering a composition comprising a mutant ChR2 to a subject to preserve, improve, or restore phototransduction. Preferably, the compositions and methods of the invention are provided to a subject having impaired vision, thereby restoring vision to normal levels.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application is a continuation application of U.S. patent application Ser. No. 14 / 383,211, filed Sep. 5, 2014, now U.S. Pat. No. 10,947,281, issued Mar. 16, 2021, which is a national stage application filed under 35 U.S.C. § 371, of International Application No. PCT / US2013 / 029171, filed on Mar. 5, 2013, which claims the benefit of and priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 61 / 606,663, filed on Mar. 5, 2012, the contents of each of which are incorporated by reference herein in their entireties.GOVERNMENT SUPPORT[0002]This invention was made with U.S. Government support under the National Institutes of Health / National Eye Institute grant NIH EY 17130. The Government has certain rights in the invention.DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY[0003]The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/405A61K38/16C07K14/00A61P27/02
CPCC07K14/405A61K38/16A61K48/00A61P27/02C07K14/00
Inventor PAN, ZHUO-HUA
Owner WAYNE STATE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com